Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/4/2025

Retinal Vasculitis Treatment Guidelines

Diagnosis and Initial Assessment

  • The American Academy of Ophthalmology recommends determining if retinal vasculitis is isolated ocular disease or part of a systemic condition, associated with infectious vs. non-infectious etiology, and acute or chronic, with evaluation for giant cell arteritis (GCA) in patients over 50, using targeted serologies and ESR, CRP to rule out GCA 1, 2
  • Key diagnostic workup includes assessing symptoms (acute or chronic), checking for signs of GCA (temporal tenderness, jaw claudication, weight loss, proximal myalgia, fever, elevated CRP and/or ESR) in patients over 50 years, and using specific serologies (e.g., antineutrophil cytoplasmic antibodies (ANCA)) for diagnosing autoimmune vasculitis and targeted serologies for suspected infectious causes 2, 1
  • Testing for systemic vasculitis markers, such as ANCA, is important when suspecting systemic vasculitis, and specific antibody tests are more appropriate than general immunoglobulin levels for suspected inflammatory or autoimmune causes, as recommended by the American College of Rheumatology 2, 3

Treatment

  • The American College of Rheumatology recommends immediate high-dose systemic corticosteroids (1 mg/kg/day prednisolone, max 60 mg/day) as first-line therapy, with consideration of immunosuppressive agents as adjunctive therapy based on etiology, severity, and response to initial treatment, and maintenance for one month, then tapering gradually 4
  • The American Academy of Ophthalmology recommends considering immunosuppressive agents when there is an inadequate response to corticosteroids, corticosteroid-related adverse events, or need for long-term therapy, with options including mycophenolate mofetil, methotrexate, azathioprine, calcineurin inhibitors, and adalimumab (Grade B recommendation) 5
  • High-dose systemic corticosteroids should be maintained for one month, then tapered gradually, with consideration of IV methylprednisolone for patients with early visual symptoms and bone protection therapy, as recommended by the American College of Rheumatology 4

Special Considerations

  • For acute retinal artery occlusion, urgent referral to a stroke center is recommended due to high risk of concurrent cerebrovascular accident, with consideration of hyperbaric oxygen therapy (100% oxygen over 9 hours) and evaluation for silent brain infarction and DWI-MRI abnormalities 1, 6
  • Regular ophthalmologic follow-up is necessary to monitor for treatment response, development of retinal or iris neovascularization, and neovascular glaucoma, with panretinal photocoagulation (PRP) recommended if neovascularization develops and consideration of anti-VEGF agents when hemorrhage is present, as recommended by the American Academy of Ophthalmology 1
  • Patients with retinal emboli should be aware of the potential for subsequent stroke and systemic implications, and evaluation should not be delayed, as retinal emboli represent a medical emergency with systemic implications, with <10% of non-arteritic CRAO patients experiencing meaningful visual recovery 1

Common Pitfalls

  • Failure to initiate adequate corticosteroid dose early is the most common reason for treatment failure, with inadequate initial dosing reducing effectiveness, and neglecting systemic associations may lead to delayed diagnosis and treatment of underlying systemic disease, as recommended by the American Academy of Ophthalmology 1
  • Failure to screen for GCA in patients over 50 requires immediate treatment to prevent vision loss in the fellow eye, and neglecting stroke risk in patients with acute retinal artery occlusion requires urgent referral for stroke evaluation, as recommended by the American Academy of Ophthalmology 1